Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02078661 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of PG101 for Dry Eye Syndrome
A Phase 1 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02078661 is a Phase 1 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 72 participants.
The verdict
NCT02078661, a Phase 1 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of 0.25% PG101 and 1.0% PG101 topical gel suspension compared to placebo when administered two times daily for 14 days in subjects diagnosed with dry eye syndrome
Interventions
- DRUG PG101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02078661
The ClinicalTrials.gov registry entry for NCT02078661 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PG101 is the first listed.
NCT02078661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02078661 about?
NCT02078661 is a clinical study titled "Safety and Efficacy of PG101 for Dry Eye Syndrome". To evaluate the safety and efficacy of 0.25% PG101 and 1.0% PG101 topical gel suspension compared to placebo when administered two times daily for 14 days in subjects diagnosed with dry eye syndrome
What is the current status of trial NCT02078661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2013-12. Estimated completion is 2014-01.
What interventions are being tested in trial NCT02078661?
The interventions under investigation include: PG101 (DRUG).
Who is sponsoring clinical trial NCT02078661?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.